Then, our lipid clinic is a hub for the management of HeFH and other severe hyperlipidaemias, so our cohort could be different compared to one of the cardiology units, managing more coronary heart disease patients, for whom PCSK9 inhibitors are more easily reimbursed. This evidence concerns the gene PCSK9 and hyperlipidemia.